Researchers from the Mayo Clinic recently found that mutations in the enzyme IDH1 have a significant negative impact on the survival of patients with myelodysplastic syndromes.
In particular, the researchers found that myelodysplastic syndromes (MDS) patients with IDH1 mutations had a median overall survival of only 3 months compared to 29 months for MDS patients without the mutation.
This result, the authors write, “suggests a powerful adverse prognostic effect for mutant IDH1 in MDS.”
Isocitrate dehydrogenase (IDH) is an enzyme that plays an important role in the citric acid cycle,…
Myelodysplastic syndromes patients who receive stem cell transplants from matched unrelated donors experience higher overall survival rates than patients who receive transplants from related donors with one mismatch, according to a retrospective study performed in Japan.
However, the study authors pointed out that this finding was only significant for patients with standard-risk disease. In patients with high-risk disease, the differences in survival were not statistically significant.
In addition, patients with standard-risk disease who received transplants from related donors with a mismatch at the HLA B gene experienced lower overall survival…
Researchers from the Mayo Clinic have published results of a study investigating whether immune system proteins called cytokines are linked to the prognosis of myelodysplastic syndromes patients.
Cytokines are hormone-like molecules used by the body to transmit signals between cells. Most of the time, cytokines transmit signals related to immune system issues — for example, whether more white blood cells are needed in a specific part of the body to fight an infection.
During the course of their study, the Mayo researchers found that myelodysplastic syndromes patients with abnormally high levels of…